Q-omics provides the consensus-scored MIR2052HG profile across patient tissues and cancer cell-line models. MIR2052HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR2052HG is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MIR2052HG RNA expression shows 15,304 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where MIR2052HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2052HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2052HG survival associations across molecular data types. MIR2052HG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2052HG RNA expression–survival associations across cancer types. High MIR2052HG expression shows unfavorable associations in STAD, LGG, COAD and KIRC, but favorable associations in UCS and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR2052HG RNA expression.
This table summarizes MIR2052HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2052HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2052HG shows higher tumor expression in HNSC, LUSC, BLCA, STAD, LIHC and LUAD. The HNSC box plot shows higher MIR2052HG RNA expression in tumor versus normal tissue (log2 FC = +0.427, t-test p < 0.001).
This table shows molecular features associated with MIR2052HG in patient tissues and cancer cell lines. In patient samples, MIR2052HG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
